Ewing's sarcoma

(redirected from Ewing sarcoma)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Ewing sarcoma: osteosarcoma

Ewing's sarcoma

(ˈjuːɪŋz)
n
(Pathology) a form of malignant bone tumour most commonly found in children and young people. Also called: peripheral primitive neuroectodermal tumour
[C20: named after James Ewing (1866–1943), US pathologist who first described it]
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

Ew′ing's sarco′ma

(ˈyu ɪŋz)
n.
a malignant stem-cell bone tumor, usually occurring in the leg or pelvis of children and young adults, characterized by pain, fever, and swelling.
[after James Ewing (1866–1943), U.S. pathologist, who described it]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.Ewing's sarcoma - malignant tumor in bone marrow (usually in the pelvis or in long bones)
sarcoma - a usually malignant tumor arising from connective tissue (bone or muscle etc.); one of the four major types of cancer
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the U.S.
Salarius recently completed a USD 6.4m private placement, which combined with cash from Flex Pharma, is expected to fund the combined company to mid-2020, allowing it to report early cohort data from an ongoing Phase 1 Ewing sarcoma trial.
Salarius' lead compound, Seclidemstat, targets the epigenetic dysregulation underlying Ewing sarcoma, a devastating pediatric, adolescent, and young adult bone and soft-tissue cancer for which no approved targeted therapies are currently available.
The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Pediatric Rare Disease Designation by the US Food and Drug Administration.
Primary extra skeletal ewing sarcoma presenting as soft tissue mass diagnosed on fine needle aspiration cytology.
Tragedy hit when she was diagnosed with Ewing Sarcoma which is a bone cancer.
According to the companies, the key objective of the Phase I dose-escalation trial (EUDRACT Number 2017-001263-20) is to evaluate the safety and activity, as well as to identify the optimum systemically-administered dose of radiation to treat patients with any of the following solid tumors expressing NTSR1: pancreatic ductal adenocarcinoma, colorectal cancer, gastric cancer, gastrointestinal stromal tumors, Ewing sarcoma and squamous cell carcinoma of the head and neck.
Histopathological examination of primary renal Ewing sarcoma. The tumours were in the renal pelvis and ureter, infiltrating to the renal parenchyma.
The 58 chapters address the bone microenvironment, markers of bone cancer, Ewing sarcoma, cytogenetics, animal models, imaging of bone metastases, pain management, and the cellular and molecular actions of new drugs for treating bone metastases secondary to breast and prostate cancers.